Trial Profile

A Randomized, Double-Blind, Phase III Multi-Center Study Evaluating the Safety and Efficacy of BF-200 ALA Versus Placebo in the Treatment of Actinic Keratosis (AK) When Using PDT

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Apr 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Feb 2016 Results from this trial will be presented at the 14th Annual South Beach Symposium, according to a Biofrontera media release.
27 Jan 2011 Biofrontera has received a positive interim report of the responsible committee of the European Medicines Agency, according to a company media release.
16 Dec 2010 According to a Biofrontera media release, EMEA has sent official summaries and preliminary questions of the reviewers about the approval dossier, and subject to satisfactory answers to the questions raised, the review will recommended the drug approval.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com